RADX

Radiopharm Theranostics Limited

Price Chart

No historical data available

Latest Quote

$2.19

-0.23 (-9.34%)

Current Price

Previous Close	$2.41
Open	$2.37
Day High	$2.44
Day Low	$2.19
Volume	38,071

Fetched: 2026-08-31T18:10:48

Stock Information

Note: Financial values converted from AUD to USD

Shares Outstanding	14.46M
Cash Equivalents	$2.97M
Revenue	$9.06M
Net Income	$-39.53M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$31.59M
EPS (TTM)	$-3.86
Exchange	NCM

🌐 Visit Website

Recent Price History

No history data available. Data will be fetched automatically.

About Radiopharm Theranostics Limited

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.

📰 Latest News

Radiopharm Theranostics Highlights Phase 1 Pipeline, Eyes June RAD 101 Data at DB Conference

MarketBeat • 2026-04-29T09:04:38Z

Radiopharm Theranostics ADR (RADX): Inside the Clinical Programs

Insider Monkey • 2026-04-28T17:29:48Z

Inside Biotech: Radiopharm advances RAD 402 into clinic with first patient dosed in Phase 1 trial

Proactive • 2026-03-26T23:20:00Z

Radiopharm Theranostics Shares RAD101 Phase IIb Update: 90% Hit Primary Endpoint in Brain Mets Study

MarketBeat • 2026-03-25T08:32:23Z

Radiopharm Theranostics Highlights 90% Positive RAD101 Interim Data, Eyes Phase III FDA Talks

MarketBeat • 2026-03-25T07:33:01Z

Favourable Signals For Radiopharm Theranostics: Numerous Insiders Acquired Stock

Simply Wall St. • 2025-12-22T00:57:27Z

Radiopharm (RADX) Sees Slight Pessimism From Analysts

Insider Monkey • 2025-12-15T17:35:45Z

Top Midday Gainers

MT Newswires • 2025-12-15T17:28:27Z

Radiopharm Theranostics Expects to Raise $22.7 Million Via Private Placement, Shares Down Pre-Bell

MT Newswires • 2025-10-20T12:23:51Z

Radiopharm receives DSMC recommendation to advance Phase 1 ‘HEAT’ trial

TipRanks • 2025-10-02T12:15:46Z

Period:

Income Statement (Annual)

Metric	2025-06-30	2024-06-30	2023-06-30	2022-06-30
Revenue
Reconciled Cost Of Revenue	$2,570,185	$0	$0	-
Cost Of Revenue	$2,570,185	$0	$0	-
Total Revenue	$2,598,271	$213,979	$209,067	$6,315
Operating Revenue	$2,598,271	$213,979	$209,067	$6,315
Expenses
Interest Expense	$46,696	$459,731	$61,564	$6,686,027
Total Expenses	$27,369,966	$26,797,137	$22,871,112	$14,248,559
Other Income Expense	$-2,811,455	$-7,475,104	$-2,103,498	$-735,477
Net Non Operating Interest Income Expense	$238,207	$-161,388	$42,151	$-6,686,027
Total Other Finance Cost	$350,248	$-262,242	-	-
Interest Expense Non Operating	$46,696	$459,731	$61,564	$6,686,027
Operating Expense	$24,799,781	$26,797,137	$22,871,112	$14,248,559
Other Operating Expenses	$-6,699,474	$-924,326	$-4,231,611	$1,149,027
General And Administrative Expense	$11,817,814	$11,207,016	$10,914,176	$8,017,841
Other Non Operating Income Expenses	-	$-5,411,742	$4,231,611	$-735,477
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-27,418,807	$-34,288,560	$-24,750,570	$-21,695,496
Net Interest Income	$238,207	$-161,388	$42,151	$-6,686,027
Interest Income	$635,152	$36,101	$103,715	-
Normalized Income	$-25,450,788	$-29,055,987	$-23,278,121	$-21,180,662
Net Income From Continuing And Discontinued Operation	$-27,418,807	$-34,288,560	$-24,750,570	$-21,695,496
Total Operating Income As Reported	$-27,298,247	$-33,759,919	$-24,661,828	-
Net Income Common Stockholders	$-27,418,807	$-34,288,560	$-24,750,570	$-21,695,496
Net Income	$-27,418,807	$-34,288,560	$-24,750,570	$-21,695,496
Net Income Including Noncontrolling Interests	$-27,418,807	$-34,288,560	$-24,750,570	$-21,695,496
Net Income Continuous Operations	$-27,418,807	$-34,288,560	$-24,750,570	$-21,695,496
Pretax Income	$-27,344,943	$-34,219,650	$-24,723,392	$-21,663,747
Special Income Charges	$-2,910,240	$-7,543,013	$-1,919,537	-
Interest Income Non Operating	$635,152	$36,101	$103,715	-
Operating Income	$-24,771,695	$-26,583,158	$-22,662,045	$-14,242,244
Depreciation Amortization Depletion Income Statement	$5,242	$5,388	$4,686	$2,132,068
Depreciation And Amortization In Income Statement	$5,242	$5,388	$4,686	$2,132,068
Depreciation Income Statement	$5,242	$5,388	$4,686	$837
Gross Profit	$28,086	$213,979	$209,067	$6,315
Amortization Of Intangibles Income Statement	-	$2,230,229	$2,352,674	$2,131,231
Per Share
Diluted EPS	$-3.78	$-26.62	$-22.94	$-32.79
Basic EPS	$-3.78	$-26.62	$-22.94	$-32.79
Other
Tax Effect Of Unusual Items	$-843,437	$-2,242,531	$-631,050	$-220,643
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-24,481,549	$-26,279,427	$-22,553,644	$-12,110,175
Total Unusual Items	$-2,811,455	$-7,475,104	$-2,103,498	$-735,477
Total Unusual Items Excluding Goodwill	$-2,811,455	$-7,475,104	$-2,103,498	$-735,477
Reconciled Depreciation	$5,242	$5,388	$4,686	$2,132,068
EBITDA (Bullshit earnings)	$-27,293,004	$-33,754,531	$-24,657,142	$-12,845,652
EBIT	$-27,298,247	$-33,759,919	$-24,661,828	$-14,977,721
Diluted Average Shares	$4,970,926	$921,196	$771,874	$473,194
Basic Average Shares	$4,960,571	$921,196	$771,874	$473,194
Diluted NI Availto Com Stockholders	$-27,418,807	$-34,288,560	$-24,750,570	-
Tax Provision	$73,864	$68,910	$27,177	$31,748
Gain On Sale Of Ppe	$0	$-1,206,944	$0	-
Restructuring And Mergern Acquisition	$2,910,240	$6,336,069	$1,919,537	-
Gain On Sale Of Security	$98,785	$67,909	$-183,961	$-735,477
Research And Development	$19,676,199	$16,509,059	$16,183,861	$2,949,623
Selling General And Administration	$11,817,814	$11,207,016	$10,914,176	$8,017,841
Other Gand A	$3,149,865	$2,305,295	$3,854,239	$1,408,479
Insurance And Claims	$75,631	$256,871	$490,141	-
Salaries And Wages	$8,592,318	$8,644,850	$6,569,795	$6,609,362
Impairment Of Capital Assets	-	$1,057,560	$2,216,819	-
Amortization	-	$2,230,229	$2,352,674	$2,131,231

Fetched: 2026-08-24

Balance Sheet (Annual)

Metric	2025-06-30	2024-06-30	2023-06-30	2022-06-30
Assets
Net Tangible Assets	$-1,274,613	$-14,991,939	$-10,123,532	$4,925,208
Total Assets	$61,843,452	$51,513,409	$53,596,735	$59,626,214
Total Non Current Assets	$33,343,744	$35,174,549	$41,940,481	$40,129,355
Investmentin Financial Assets	$0	$28,604	-	-
Goodwill And Other Intangible Assets	$33,305,510	$35,102,468	$41,863,014	$40,099,623
Other Intangible Assets	$33,305,510	$35,102,468	$41,863,014	$40,099,623
Current Assets	$28,499,708	$16,338,860	$11,656,254	$19,496,859
Other Current Assets	$241,056	$206,103	$95,202	$163,628
Assets Held For Sale Current	$0	$2,143,587	-	-
Receivables	$7,437,114	$706,102	$3,195,015	$40,390
Other Receivables	$163,421	$131,883	$3,120,138	-
Taxes Receivable	$7,273,693	$574,219	-	-
Cash Cash Equivalents And Short Term Investments	$20,821,537	$13,283,067	$8,366,038	$19,292,840
Cash And Cash Equivalents	$20,821,537	$13,283,067	$8,366,038	$19,292,840
Cash Financial	$20,821,537	$13,283,067	$8,366,038	$19,292,840
Other Non Current Assets	-	$28,604	$28,604	$28,604
Accounts Receivable	-	$574,219	$74,877	$40,390
Gross Accounts Receivable	-	$574,219	$74,877	$40,390
Liabilities
Total Liabilities Net Minority Interest	$31,185,623	$31,952,991	$21,002,750	$14,601,383
Total Non Current Liabilities Net Minority Interest	$20,507,000	$19,384,504	$11,542,511	$8,967,353
Other Non Current Liabilities	$20,507,000	$19,384,504	$11,421,514	$8,858,337
Tradeand Other Payables Non Current	$0	$0	$120,997	$109,015
Non Current Deferred Liabilities	$0	$0	-	-
Current Liabilities	$10,678,623	$12,568,486	$9,460,239	$5,634,030
Other Current Liabilities	$2,446,608	$2,834,171	$5,592,608	$4,027,580
Current Deferred Liabilities	$1,230,371	$1,684,700	-	-
Payables And Accrued Expenses	$6,679,772	$7,763,726	$3,660,945	$1,539,844
Payables	$4,712,766	$6,562,036	$3,660,945	$1,539,844
Other Payable	$173,723	$1,960,689	$1,546,723	$689,129
Accounts Payable	$4,539,043	$4,601,348	$2,114,222	$850,715
Equity
Common Stock Equity	$32,030,898	$20,110,529	$31,739,482	$45,024,831
Total Equity Gross Minority Interest	$30,657,828	$19,560,418	$32,593,985	$45,024,831
Stockholders Equity	$32,030,898	$20,110,529	$31,739,482	$45,024,831
Other Equity Interest	$607,511	$607,511	$1,535,016	-
Gains Losses Not Affecting Retained Earnings	$9,379,949	$27,123,909	$7,409,509	$5,025,819
Other Equity Adjustments	$9,379,949	$27,123,909	$7,409,509	$5,025,819
Retained Earnings	$-104,214,076	$-79,618,692	$-46,734,746	$-22,042,457
Other
Ordinary Shares Number	$1,691,182,555	$329,209,873	$256,911,699	$200,064,050
Share Issued	$1,691,182,555	$329,209,873	$256,911,699	$200,064,050
Tangible Book Value	$-1,274,613	$-14,991,939	$-10,123,532	$4,925,208
Invested Capital	$32,030,898	$20,110,529	$31,739,482	$45,024,831
Working Capital	$17,821,085	$3,770,374	$2,196,015	$13,862,829
Total Capitalization	$32,030,898	$20,110,529	$31,739,482	$45,024,831
Minority Interest	$-1,373,069	$-550,112	$854,503	-
Capital Stock	$126,257,513	$71,997,800	$69,529,703	$62,041,469
Common Stock	$126,257,513	$71,997,800	$69,529,703	$62,041,469
Current Deferred Revenue	$1,230,371	$0	-	-
Pensionand Other Post Retirement Benefit Plans Current	$321,871	$285,890	$206,686	$66,605
Current Accrued Expenses	$1,967,007	$1,201,689	-	-
Investments And Advances	$0	$28,604	-	-
Net PPE	$38,234	$43,476	$48,863	$1,128
Foreign Currency Translation Adjustments	-	$-389,257	-	-
Available For Sale Securities	-	$28,604	-	-
Gross PPE	-	$43,476	$48,863	$1,128
Machinery Furniture Equipment	-	$43,476	$48,863	$1,128

Fetched: 2026-08-24

Cash Flow Statement (Annual)

Metric	2025-06-30	2024-06-30	2023-06-30	2022-06-30
Free Cash Flow
Free Cash Flow	$-26,205,292	$-16,430,161	$-17,686,271	$-27,355,769
Operating Activities
Cash Flowsfromusedin Operating Activities Direct	$-26,205,292	$-16,430,161	$-16,591,676	$-7,090,714
Classesof Cash Receiptsfrom Operating Activities	$3,828,642	$3,655,822	$1,321,192	$-7,090,714
Other Cash Paymentsfrom Operating Activities	-	$3,469,565	$1,112,125	-
Other Cash Receiptsfrom Operating Activities	-	$3,469,565	$1,112,125	-
Investing Activities
Investing Cash Flow	$1,266,160	$-228,833	$-1,094,595	$-20,287,344
Cash Flow From Continuing Investing Activities	$1,266,160	$-228,833	$-1,094,595	$-20,287,344
Net Other Investing Changes	$-877,427	$-228,833	-	$-28,604
Capital Expenditure	-	-	$-1,094,595	$-20,265,054
Financing Activities
Issuance Of Capital Stock	$38,599,761	$21,199,605	$7,202,915	$50,057,212
Financing Cash Flow	$32,488,238	$21,593,927	$6,591,670	$46,560,440
Cash Flow From Continuing Financing Activities	$32,488,238	$21,593,927	$6,591,670	$46,560,440
Net Other Financing Charges	$-4,752,828	$-1,180,471	$-611,244	$-3,454,581
Net Common Stock Issuance	$38,599,761	$21,199,605	$7,202,915	$50,057,212
Common Stock Issuance	$38,599,761	$21,199,605	$7,202,915	$50,057,212
Repurchase Of Capital Stock	-	$-1,096,804	$-611,244	$-3,454,581
Other
Repayment Of Debt	$-1,358,696	$-3,694,937	$0	$-49,342
Issuance Of Debt	$0	$5,269,730	$0	$7,151
End Cash Position	$20,821,537	$13,283,067	$8,366,038	$19,292,840
Beginning Cash Position	$13,283,067	$8,366,038	$19,292,840	$19,373
Effect Of Exchange Rate Changes	$-10,636	$-17,903	$167,798	$91,085
Changes In Cash	$7,549,106	$4,934,933	$-11,094,600	$19,182,382
Net Issuance Payments Of Debt	$-1,358,696	$1,574,793	$0	$-42,191
Net Long Term Debt Issuance	$-1,358,696	$1,574,793	$0	$-42,191
Long Term Debt Payments	$-1,358,696	$-3,694,937	$0	$-49,342
Long Term Debt Issuance	$0	$5,269,730	$0	$7,151
Net Intangibles Purchase And Sale	$2,143,587	$0	$-1,062,196	$-20,263,089
Net PPE Purchase And Sale	$0	$0	$-32,398	$-1,966
Purchase Of PPE	$0	$0	$-32,398	$-1,966
Taxes Refund Paid Direct	$0	$3,469,565	$1,112,125	-
Interest Received Direct	$572,303	$36,101	$103,715	-
Classesof Cash Payments	$-30,606,237	$-20,122,084	$-18,016,583	-
Paymentsto Suppliersfor Goodsand Services	$-30,606,237	$-20,122,084	$-18,016,583	-
Receiptsfrom Customers	$3,828,642	$186,257	$209,067	$-7,090,714
Common Stock Payments	-	$-1,096,804	$-611,244	$-3,454,581
Purchase Of Intangibles	-	-	$-1,062,196	$-20,263,089
Interest Received Cfi	-	-	-	$6,315

Fetched: 2026-08-24